Apple's recent quarterly check-ins have been fairly ho-hum, but not this time! The Mac maker is back to growth after an impressive quarter, we explain what segments pushed the company over the top, and what investors can expect next quarter.

Forget that power plant off in the distance, these places have wind mills present on the horizon.

Competitors make headway against Teva Pharmaceutical's top-seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.

Will Airbnb launch its IPO in 2017? Is Macau officially on track for a recovery? Will Japan eventually become the new casino capital of the world? Fool.com contributor Seth McNew shares his insights after traveling through the regio

Use these tips to get out of debt and make the most of your credit.

It's earnings season, so we're breaking down quarterly results from two Fool favorites, Alphabet and Paypal. We hit the headline numbers, key metrics, and dig through management's comments to catch all the info investors need to know.

Aircraft production is basically a duopoloy with just two major players – here’s what investors need to know.

From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings,  to Aetna and Humana's $37 billion merger bust, we dive into the details behind this week's biggest healthcare stories.

Take two leading companies in the eyewear industry, combine them, and what do you get? In this case, say hello to EssilorLuxottica, a massive enterprise that will boast 140,000 employees,  $16 billion of annual revenue, and a global scale that overshadows its closest competitors by a wide margin.